AGL vs. PGNY, SHC, STAA, AMN, PDCO, IART, VCEL, DNLI, GH, and PRVA
Should you be buying agilon health stock or one of its competitors? The main competitors of agilon health include Progyny (PGNY), Sotera Health (SHC), STAAR Surgical (STAA), AMN Healthcare Services (AMN), Patterson Companies (PDCO), Integra LifeSciences (IART), Vericel (VCEL), Denali Therapeutics (DNLI), Guardant Health (GH), and Privia Health Group (PRVA). These companies are all part of the "medical" sector.
agilon health (NYSE:AGL) and Progyny (NASDAQ:PGNY) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership, earnings and community ranking.
Progyny has lower revenue, but higher earnings than agilon health. agilon health is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.
94.9% of Progyny shares are owned by institutional investors. 3.2% of agilon health shares are owned by company insiders. Comparatively, 12.3% of Progyny shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Progyny had 4 more articles in the media than agilon health. MarketBeat recorded 28 mentions for Progyny and 24 mentions for agilon health. agilon health's average media sentiment score of 0.14 beat Progyny's score of 0.04 indicating that agilon health is being referred to more favorably in the media.
Progyny received 35 more outperform votes than agilon health when rated by MarketBeat users. Likewise, 74.34% of users gave Progyny an outperform vote while only 52.69% of users gave agilon health an outperform vote.
agilon health presently has a consensus target price of $9.32, suggesting a potential upside of 79.60%. Progyny has a consensus target price of $46.11, suggesting a potential upside of 67.49%. Given agilon health's higher probable upside, equities analysts clearly believe agilon health is more favorable than Progyny.
Progyny has a net margin of 5.53% compared to agilon health's net margin of -5.67%. Progyny's return on equity of 11.95% beat agilon health's return on equity.
agilon health has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Comparatively, Progyny has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500.
Summary
Progyny beats agilon health on 15 of the 18 factors compared between the two stocks.
Get agilon health News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
agilon health Competitors List
Related Companies and Tools
